These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2202785)

  • 1. Disturbance of the 5-hydroxytryptamine metabolism in brains from patients with Alzheimer's dementia.
    Gottfries CG
    J Neural Transm Suppl; 1990; 30():33-43. PubMed ID: 2202785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A post-mortem study of noradrenergic, serotonergic and GABAergic neurons in Alzheimer's disease.
    Reinikainen KJ; Paljärvi L; Huuskonen M; Soininen H; Laakso M; Riekkinen PJ
    J Neurol Sci; 1988 Mar; 84(1):101-16. PubMed ID: 2452858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-Hydroxytryptamine-sensitive [3H]imipramine binding of protein nature in the human brain. II. Effect of normal aging and dementia disorders.
    Marcusson JO; Alafuzoff I; Bäckström IT; Ericson E; Gottfries CG; Winblad B
    Brain Res; 1987 Nov; 425(1):137-45. PubMed ID: 3427415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concentrations of serotonin and its related substances in the cerebrospinal fluid in patients with Alzheimer type dementia.
    Tohgi H; Abe T; Takahashi S; Kimura M; Takahashi J; Kikuchi T
    Neurosci Lett; 1992 Jul; 141(1):9-12. PubMed ID: 1508406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of citalopram, a selective 5-HT reuptake blocker, in emotionally disturbed patients with dementia.
    Gottfries CG; Nyth AL
    Ann N Y Acad Sci; 1991; 640():276-9. PubMed ID: 1776751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple biochemical deficits in both gray and white matter of Alzheimer brains.
    Gottfries CG; Bartfai T; Carlsson A; Eckernäs S; Svennerholm L
    Prog Neuropsychopharmacol Biol Psychiatry; 1986; 10(3-5):405-13. PubMed ID: 3797685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for decreased transport of tryptophan hydroxylase in Alzheimer's disease.
    Burke WJ; Park DH; Chung HD; Marshall GL; Haring JH; Joh TH
    Brain Res; 1990 Dec; 537(1-2):83-7. PubMed ID: 1707735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biogenic amines and their metabolites in Alzheimer's disease: noradrenaline, 5-hydroxytryptamine and 5-hydroxyindole-3-acetic acid depleted in hippocampus but not in substantia innominata.
    Baker GB; Reynolds GP
    Neurosci Lett; 1989 May; 100(1-3):335-9. PubMed ID: 2474777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ascending monoaminergic systems alterations in Alzheimer's disease. translating basic science into clinical care.
    Trillo L; Das D; Hsieh W; Medina B; Moghadam S; Lin B; Dang V; Sanchez MM; De Miguel Z; Ashford JW; Salehi A
    Neurosci Biobehav Rev; 2013 Sep; 37(8):1363-79. PubMed ID: 23707776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indoleamine concentrations in cerebrospinal fluid from patients with Alzheimer type and Binswanger type dementias before and after administration of citalopram, a synthetic serotonin uptake inhibitor.
    Tohgi H; Abe T; Takahashi S; Saheki M; Kimura M
    J Neural Transm Park Dis Dement Sect; 1995; 9(2-3):121-31. PubMed ID: 8526997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoamine metabolism in senile dementia of Alzheimer type.
    Cross AJ; Crow TJ; Johnson JA; Joseph MH; Perry EK; Perry RH; Blessed G; Tomlinson BE
    J Neurol Sci; 1983; 60(3):383-92. PubMed ID: 6195313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical changes in dementia disorders of Alzheimer type (AD/SDAT).
    Gottfries CG; Adolfsson R; Aquilonius SM; Carlsson A; Eckernäs SA; Nordberg A; Oreland L; Svennerholm L; Wiberg A; Winblad B
    Neurobiol Aging; 1983; 4(4):261-71. PubMed ID: 6200784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurochemical aspects on aging and diseases with cognitive impairment.
    Gottfries CG
    J Neurosci Res; 1990 Dec; 27(4):541-7. PubMed ID: 2079715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alzheimer's disease. A critical review.
    Gottfries CG
    Compr Gerontol C; 1988 Dec; 2(1):47-62. PubMed ID: 3076510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotonin and 5-hydroxyindoleacetic acid in CSF. Difference in Parkinson's disease and dementia of the Alzheimer's type.
    Volicer L; Direnfeld LK; Freedman M; Albert ML; Langlias PJ; Bird ED
    Arch Neurol; 1985 Feb; 42(2):127-9. PubMed ID: 2579625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of brain 5-hydroxytryptamine turnover in freely moving rats using repeated sampling of cerebrovascular fluid.
    Sarna GS; Hutson PH; Tricklebank MD; Curzon G
    J Neurochem; 1983 Feb; 40(2):383-8. PubMed ID: 6185635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes of biogenic amines and their metabolites in postmortem brains from patients with Alzheimer-type dementia.
    Arai H; Kosaka K; Iizuka R
    J Neurochem; 1984 Aug; 43(2):388-93. PubMed ID: 6204013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholinergic deficit in Alzheimer's disease: a study based on CSF and autopsy data.
    Reinikainen KJ; Riekkinen PJ; Paljärvi L; Soininen H; Helkala EL; Jolkkonen J; Laakso M
    Neurochem Res; 1988 Feb; 13(2):135-46. PubMed ID: 3362291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of 5-hydroxytryptamine uptake blockers on the concentration in brain of 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in male rats, pro-oestrous rats and ovariectomized rats treated with oestrogen and progesterone.
    Horn AM; Watts AG
    J Endocrinol; 1985 Mar; 104(3):407-13. PubMed ID: 2579182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurotransmitter and receptor deficits in senile dementia of the Alzheimer type.
    Quirion R; Martel JC; Robitaille Y; Etienne P; Wood P; Nair NP; Gauthier S
    Can J Neurol Sci; 1986 Nov; 13(4 Suppl):503-10. PubMed ID: 2878714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.